ArticleEuropean journal of neurology2025
New-Onset Headache After SARS-CoV-2 Infection and Vaccination: Results From Three Population-Based Cohorts in Norway.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Association of Headache and Physical Activity in Times of the COVID-19 Pandemic: A Prospective Cohort Study.Brain and behavior · 2026Article
- New-Onset Headache After SARS-CoV-2 Infection and Vaccination: Results From Three Population-Based Cohorts in Norway.European journal of neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPersistent headache after SARS-CoV-2 infections and vaccination has been reported. However, limited data exist on the risk of new-onset headache after these exposures compared to unexposed periods in the general population.
methodsWe used data from three population-based cohorts (N = 85,774, age 19-81 years). SARS-CoV-2 infections and vaccinations were obtained from national registries and questionnaires. Before and after Omicron emergence, participants stated whether they had been suffering from headache during the past year, reported headache characteristics, and time of onset. Time-dependent exposures were used to investigate the impact of SARS-CoV-2 infection and vaccination on the risk of new-onset headache. Headache subtypes were secondary outcomes.
resultsSARS-CoV-2 infection and first and second vaccine doses were associated with increased risk of new-onset headache. The three cohorts, representing different age groups, were analyzed separately. For pre-Omicron infections, the hazard ratio (HR) was 6.7 (95% confidence interval (CI) 4.8-9.2) and 6.5 (95% CI 3.8-11.1) among middle-aged women and men, respectively. For Omicron infection, HRs were 4.7 (95% CI 4.1-5.4) and 4.5 (95% CI 3.7-5.4), respectively. The risk increased with infection severity. Corresponding HRs for first and second vaccine doses, administered during low transmission, were 1.6 and 1.7, respectively, in women, and 1.5 for both doses in men. The third dose, given before the Omicron surge, was associated with 20%-40% protection against new-onset headache.
conclusionsSARS-CoV-2 infection was strongly associated with new-onset headache. Primary vaccination was associated with a small increased risk of headache during a low-transmission period, whereas booster vaccination offered protection during high-transmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.